arrow
B

Barbara Hutter

nct heidelberg
H指数:58
被引数:3.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinically actionable genomic and transcriptomic landscape of advanced neuroendocrine neoplasms

晚期神经内分泌肿瘤的临床可操作基因组学和转录组学景观

Med
IF11.8
2026-04-300
OAAI
Multi-layered molecular profiling informs the diagnosis and targeted therapy of desmoplastic small round cell tumor

多层分子分析为硬化性小圆细胞肿瘤的诊断和靶向治疗提供信息

2026-04-090
OA
The Knowledge Connector decision support system for multiomics-based precision oncology

基于多组学的精准肿瘤学知识连接器决策支持系统

2026-01-190
OAAI
CDK4/6 inhibition in advanced chordoma: final results of the NCT PMO-1601 trial

CDK4/6抑制剂在晚期软骨肉瘤中的应用:NCT PMO-1601试验的最终结果

2025-07-070
OA
Comprehensive genomic and transcriptomic analysis enables molecularly guided therapy options in peritoneal and pleural mesothelioma

全面的基因组学和转录组学分析能够实现针对腹膜和胸膜间皮瘤的分子引导治疗方案。

2025-04-010
OAAI
NCT/DKFZ MASTER handbook of interpreting whole-genome, transcriptome, and methylome data for precision oncology
2023-10-267
OAAI
Genomics-based personalized oncology of advanced thymic epithelial tumors
2023-04-040
PRE
Comprehensive analysis of mutational signatures reveals distinct patterns and molecular processes across 27 pediatric cancers

突变特征的综合分析揭示了27种儿科癌症的不同模式和分子过程

2023-01-2623
OAAI
Comprehensive molecular profiling of sarcomas in adolescent and young adult patients: Results of the EORTC SPECTA-AYA international proof-of-concept study

青少年和年轻成人患者肉瘤的综合分子谱分析: EORTC specta-aya国际概念验证研究的结果

2023-01-016
OA
Author Correction: Genomic footprints of activated telomere maintenance mechanisms in cancer (Dec, 10.1038/s41467-019-13824-9, 2022)

作者更正: 癌症中活化端粒维持机制的基因组足迹 (12月,10.1038/s41467-019-13824-9,2022)

2022-12-080
OAAI
Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancers
2022-11-0128
OA
Comprehensive genomic and epigenomic analysis in cancer of unknown primary guides molecularly- informed therapies despite heterogeneity
2022-08-0227
OAAI
Rationale and design of the CRAFT (Continuous ReAssessment with Flexible ExTension in Rare Malignancies) multicenter phase II trial
2021-12-016
OAAI
Comprehensive genomic characterization of gene therapy-induced T-cell acute lymphoblastic leukemia (vol 34, pg 2785, 2020)
LEUKEMIA
IF13.4
2021-11-160
OAAI
Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers

全面的基因组和转录组学分析可指导罕见癌症患者的治疗决策

2021-06-10150
OA
Framework for quality assessment of whole genome cancer sequences
2020-10-077
OAAI